149.86
price down icon1.47%   -2.23
after-market After Hours: 148.64 -1.22 -0.81%
loading
Illumina Inc stock is traded at $149.86, with a volume of 1.85M. It is down -1.47% in the last 24 hours and up +11.05% over the past month. Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$152.09
Open:
$152.42
24h Volume:
1.85M
Relative Volume:
1.02
Market Cap:
$22.90B
Revenue:
$4.29B
Net Income/Loss:
$703.00M
P/E Ratio:
33.57
EPS:
4.4635
Net Cash Flow:
$993.00M
1W Performance:
-1.72%
1M Performance:
+11.05%
6M Performance:
+36.39%
1Y Performance:
+12.16%
1-Day Range:
Value
$148.49
$152.78
1-Week Range:
Value
$147.57
$155.53
52-Week Range:
Value
$68.70
$155.53

Illumina Inc Stock (ILMN) Company Profile

Name
Name
Illumina Inc
Name
Phone
(858) 202-4500
Name
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Name
Employee
8,970
Name
Twitter
@illumina
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ILMN's Discussions on Twitter

Compare ILMN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
ILMN
Illumina Inc
149.86 23.24B 4.29B 703.00M 993.00M 4.4635
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
608.02 234.41B 43.74B 6.58B 6.11B 17.31
Diagnostics & Research icon
DHR
Danaher Corp
224.54 166.52B 24.27B 3.50B 5.02B 4.8589
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
687.74 55.48B 4.17B 1.03B 940.22M 12.61
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
239.76 41.05B 15.90B 1.28B 2.21B 7.2842
Diagnostics & Research icon
A
Agilent Technologies Inc
133.87 38.54B 6.95B 1.30B 1.15B 4.5696

Illumina Inc Stock (ILMN) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-12-25 Downgrade Daiwa Securities Outperform → Neutral
Jul-11-25 Downgrade Scotiabank Sector Outperform → Sector Perform
Mar-04-25 Reiterated Citigroup Neutral
Feb-28-25 Downgrade HSBC Securities Buy → Hold
Feb-10-25 Downgrade Barclays Equal Weight → Underweight
Feb-07-25 Downgrade TD Cowen Buy → Hold
Dec-11-24 Downgrade Citigroup Buy → Neutral
Nov-12-24 Resumed Morgan Stanley Equal-Weight
Oct-17-24 Upgrade HSBC Securities Hold → Buy
Aug-28-24 Upgrade Argus Hold → Buy
Aug-16-24 Upgrade Daiwa Securities Neutral → Buy
Aug-14-24 Upgrade Barclays Underweight → Equal Weight
Aug-14-24 Upgrade TD Cowen Hold → Buy
Jul-10-24 Upgrade Citigroup Neutral → Buy
Jun-03-24 Resumed Jefferies Hold
Jan-16-24 Downgrade HSBC Securities Buy → Hold
Jan-04-24 Downgrade TD Cowen Outperform → Market Perform
Dec-18-23 Upgrade Scotiabank Sector Perform → Sector Outperform
Dec-15-23 Upgrade Bernstein Underperform → Mkt Perform
Dec-14-23 Initiated Guggenheim Buy
Dec-14-23 Initiated Stephens Overweight
Dec-13-23 Initiated Wolfe Research Outperform
Dec-12-23 Downgrade BofA Securities Neutral → Underperform
Dec-11-23 Upgrade Citigroup Sell → Neutral
Nov-10-23 Downgrade Canaccord Genuity Buy → Hold
Sep-28-23 Initiated Bernstein Underperform
Jul-05-23 Resumed JP Morgan Neutral
Jan-25-23 Downgrade Argus Buy → Hold
Jan-05-23 Initiated Scotiabank Sector Perform
Dec-12-22 Downgrade Citigroup Neutral → Sell
Dec-07-22 Initiated RBC Capital Mkts Outperform
Oct-04-22 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-28-22 Upgrade Evercore ISI In-line → Outperform
Aug-25-22 Initiated Credit Suisse Neutral
Jul-13-22 Downgrade Barclays Equal Weight → Underweight
Jan-18-22 Upgrade Stifel Hold → Buy
Jan-11-22 Upgrade Barclays Underweight → Equal Weight
Jan-07-22 Upgrade BofA Securities Underperform → Neutral
Jan-06-22 Resumed Morgan Stanley Equal-Weight
Jan-06-22 Resumed Piper Sandler Overweight
Oct-15-21 Resumed Cowen Outperform
Aug-19-21 Downgrade SVB Leerink Outperform → Mkt Perform
Jun-01-21 Upgrade Evercore ISI Underperform → In-line
Mar-31-21 Downgrade Atlantic Equities Overweight → Neutral
Mar-31-21 Upgrade Canaccord Genuity Hold → Buy
Mar-03-21 Initiated Barclays Underweight
Dec-22-20 Upgrade Piper Sandler Neutral → Overweight
Dec-17-20 Upgrade BTIG Research Neutral → Buy
Oct-13-20 Downgrade Guggenheim Buy → Neutral
Sep-30-20 Initiated Atlantic Equities Overweight
Sep-29-20 Downgrade Wolfe Research Outperform → Peer Perform
Sep-22-20 Downgrade Stifel Buy → Hold
Sep-22-20 Downgrade UBS Buy → Neutral
Sep-21-20 Upgrade Guggenheim Neutral → Buy
Sep-21-20 Downgrade JP Morgan Overweight → Neutral
Sep-09-20 Initiated Morgan Stanley Equal-Weight
Aug-07-20 Downgrade Evercore ISI In-line → Underperform
Aug-07-20 Downgrade Piper Sandler Overweight → Neutral
Jul-07-20 Downgrade Guggenheim Buy → Neutral
Apr-24-20 Downgrade Citigroup Buy → Neutral
Apr-21-20 Downgrade Robert W. Baird Outperform → Neutral
Jan-08-20 Initiated Wells Fargo Underweight
Jan-07-20 Initiated Citigroup Buy
Jan-02-20 Downgrade Evercore ISI Outperform → In-line
Nov-15-19 Initiated Stifel Buy
Oct-25-19 Initiated Guggenheim Buy
View All

Illumina Inc Stock (ILMN) Latest News

pulisher
Jan 28, 2026

Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products - TradingView

Jan 28, 2026
pulisher
Jan 27, 2026

Retirement Systems of Alabama Sells 7,647 Shares of Illumina, Inc. $ILMN - MarketBeat

Jan 27, 2026
pulisher
Jan 27, 2026

Illumina, Inc. $ILMN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat

Jan 27, 2026
pulisher
Jan 26, 2026

The Analyst Verdict: Illumina In The Eyes Of 15 Experts - Benzinga

Jan 26, 2026
pulisher
Jan 26, 2026

Microarrays Market Size to Accumulate Around USD 10.72 Billion by 2033, Driven by Expanding Genomics Research and Advanced Diagnostic Adoption – SNS Insider - GlobeNewswire Inc.

Jan 26, 2026
pulisher
Jan 26, 2026

Illumina price driven lower by pivotal resistanceForecast today26-01-2026 - Economies.com

Jan 26, 2026
pulisher
Jan 26, 2026

Canaccord Genuity raises Illumina stock price target to $150 on solid results - Investing.com

Jan 26, 2026
pulisher
Jan 26, 2026

Illumina Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛

Jan 26, 2026
pulisher
Jan 25, 2026

Wealth Enhancement Advisory Services LLC Buys 9,997 Shares of Illumina, Inc. $ILMN - MarketBeat

Jan 25, 2026
pulisher
Jan 25, 2026

iA Global Asset Management Inc. Purchases New Position in Illumina, Inc. $ILMN - MarketBeat

Jan 25, 2026
pulisher
Jan 25, 2026

9,062 Shares in Illumina, Inc. $ILMN Purchased by Rakuten Investment Management Inc. - MarketBeat

Jan 25, 2026
pulisher
Jan 24, 2026

Illumina Inc. (ILMN) shares see target boost as analysts see potential 2026 upside - MSN

Jan 24, 2026
pulisher
Jan 24, 2026

Is It Time To Reconsider Illumina (ILMN) After Mixed Multi Year Share Performance? - Yahoo Finance

Jan 24, 2026
pulisher
Jan 24, 2026

Customer Engagement Center - Illumina

Jan 24, 2026
pulisher
Jan 24, 2026

Baillie Gifford & Co. Lowers Stake in Illumina, Inc. $ILMN - MarketBeat

Jan 24, 2026
pulisher
Jan 23, 2026

Illumina’s billion cell atlas tries to solve artificial intelligence’s data bottleneck in biology - 2 Minute Medicine

Jan 23, 2026
pulisher
Jan 23, 2026

Whole Genome and Exome Sequencing: Global Market Review 2021-2025 and Growth Outlook 2026-2031 Featuring Illumina, Thermo Fisher Scientific, BGI Genomics and Other Leading Players - Yahoo Finance

Jan 23, 2026
pulisher
Jan 23, 2026

Illumina, Inc. $ILMN Shares Sold by Teacher Retirement System of Texas - MarketBeat

Jan 23, 2026
pulisher
Jan 23, 2026

Universal Beteiligungs und Servicegesellschaft mbH Purchases 40,166 Shares of Illumina, Inc. $ILMN - MarketBeat

Jan 23, 2026
pulisher
Jan 23, 2026

$4.5 Billion Whole Genome Sequencing Market Outlook, 2031 - GlobeNewswire

Jan 23, 2026
pulisher
Jan 23, 2026

$4.5 Billion Whole Genome Sequencing Market Outlook, 2031 Featuring Profiles of Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies and Other Leading Players - Yahoo Finance UK

Jan 23, 2026
pulisher
Jan 23, 2026

United States Agrigenomics Market | CAGR 8% | North America Leads - openPR.com

Jan 23, 2026
pulisher
Jan 22, 2026

Former Illumina Executive Moves Into Quanterix’s Corner Office - Medical Product Outsourcing

Jan 22, 2026
pulisher
Jan 22, 2026

Illumina stock hits 52-week high at 151.35 USD By Investing.com - Investing.com Australia

Jan 22, 2026
pulisher
Jan 22, 2026

Dubai Health embraces genomics to advance care and research - Illumina

Jan 22, 2026
pulisher
Jan 22, 2026

Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years - Sahm

Jan 22, 2026
pulisher
Jan 21, 2026

Life Sciences Tools & Services Stocks Q3 Teardown: Illumina (NASDAQ:ILMN) Vs The Rest - Yahoo Finance

Jan 21, 2026
pulisher
Jan 21, 2026

The Truth About Illumina Inc.: Is This Genomics Giant Still Worth Your Money? - AD HOC NEWS

Jan 21, 2026
pulisher
Jan 21, 2026

Illumina (NASDAQ:ILMN) Sets New 52-Week HighHere's What Happened - MarketBeat

Jan 21, 2026
pulisher
Jan 21, 2026

Illumina and Powell Gilbert in love with Lisbon - JUVE Patent

Jan 21, 2026
pulisher
Jan 21, 2026

Illumina stock hits 52-week high at 151.35 USD - Investing.com

Jan 21, 2026
pulisher
Jan 21, 2026

Illumina secures CMS reimbursement for cancer genomic test at $2,989 By Investing.com - Investing.com South Africa

Jan 21, 2026
pulisher
Jan 21, 2026

11,407 Shares in Illumina, Inc. $ILMN Acquired by Inscription Capital LLC - MarketBeat

Jan 21, 2026
pulisher
Jan 21, 2026

North America Bioinformatics Market Size, Share, Trends, - openPR.com

Jan 21, 2026
pulisher
Jan 20, 2026

Illumina Secures CMS Reimbursement for TruSight Oncology Test at $2,989.55 - Intellectia AI

Jan 20, 2026
pulisher
Jan 20, 2026

Illumina Gets Medicare Boost for Cancer Test, Shares Climb - Benzinga

Jan 20, 2026
pulisher
Jan 20, 2026

Evaluating next‑generation cloud compute for large‑scale genomic processing - Amazon Web Services (AWS)

Jan 20, 2026
pulisher
Jan 20, 2026

Illumina secures CMS reimbursement for TruSight™ Oncology Compre - GuruFocus

Jan 20, 2026
pulisher
Jan 20, 2026

Illumina secures CMS reimbursement for cancer genomic test at $2,989 - Investing.com

Jan 20, 2026
pulisher
Jan 20, 2026

Illumina Gets Reimbursement For FDA-Approved TruSight Oncology Comprehensive Test, Stock Down - Nasdaq

Jan 20, 2026
pulisher
Jan 20, 2026

Press Release - Illumina

Jan 20, 2026
pulisher
Jan 20, 2026

Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology - PR Newswire

Jan 20, 2026
pulisher
Jan 20, 2026

Stifel raises Illumina stock price target to $155 on growth outlook - Investing.com

Jan 20, 2026
pulisher
Jan 20, 2026

GRAIL Inc.Illumina's Divested Holy Grail (NASDAQ:GRAL) - Seeking Alpha

Jan 20, 2026
pulisher
Jan 20, 2026

Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside - Finviz

Jan 20, 2026
pulisher
Jan 20, 2026

The Technical Signals Behind (ILMN) That Institutions Follow - Stock Traders Daily

Jan 20, 2026
pulisher
Jan 20, 2026

Medicare to cover $2,989.55 Illumina genomic cancer test - Stock Titan

Jan 20, 2026
pulisher
Jan 20, 2026

Illumina: What Is Next In This Sequence? (NASDAQ:ILMN) - Seeking Alpha

Jan 20, 2026
pulisher
Jan 20, 2026

The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance - Yahoo Finance

Jan 20, 2026
pulisher
Jan 19, 2026

2MM: AI Roundup – Lilly and NVIDIA’s $1B AI lab, Illumina’s Billion Cell Atlas, AstraZeneca’s Modella deal, and Claude for Healthcare [Jan 19th, 2026] - 2 Minute Medicine

Jan 19, 2026
pulisher
Jan 19, 2026

Is Now An Opportune Moment To Examine Illumina, Inc. (NASDAQ:ILMN)? - 富途资讯

Jan 19, 2026

Illumina Inc Stock (ILMN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
diagnostics_research WAT
$385.03
price down icon 1.30%
diagnostics_research LH
$268.04
price down icon 1.14%
diagnostics_research MTD
$1,401.64
price down icon 1.65%
$235.93
price down icon 1.83%
diagnostics_research A
$133.87
price down icon 1.53%
Cap:     |  Volume (24h):